Target Gene Table
VIS IDVirusEnsembl IDGene TypeTarget GeneOncogeneTumor Suppressor GeneNCBI IDUniprot ID
TVIS30068105HIVENSG00000181072.12protein_codingCHRM2NoNo1129A4D1Q0
P08172
Q6SL56
Q6SL59
Q86SJ1
TVIS30068106HIVENSG00000181072.12protein_codingCHRM2NoNo1129A4D1Q0
P08172
Q6SL56
Q6SL59
Q86SJ1
TVIS20062080HPVENSG00000181072.12protein_codingCHRM2NoNo1129A4D1Q0
P08172
Q6SL56
Q6SL59
Q86SJ1
TVIS20061501HPVENSG00000181072.12protein_codingCHRM2NoNo1129A4D1Q0
P08172
Q6SL56
Q6SL59
Q86SJ1
TVIS20023329HPVENSG00000181072.12protein_codingCHRM2NoNo1129A4D1Q0
P08172
Q6SL56
Q6SL59
Q86SJ1
TVIS20038182HPVENSG00000181072.12protein_codingCHRM2NoNo1129A4D1Q0
P08172
Q6SL56
Q6SL59
Q86SJ1
TVIS20061739HPVENSG00000181072.12protein_codingCHRM2NoNo1129A4D1Q0
P08172
Q6SL56
Q6SL59
Q86SJ1
TVIS20043130HPVENSG00000181072.12protein_codingCHRM2NoNo1129A4D1Q0
P08172
Q6SL56
Q6SL59
Q86SJ1
TCGA Plot Options
Drug Information
GeneCHRM2
DrugBank IDDB09185
Drug NameViloxazine
Target IDBE0000560
UniProt IDP08172
Regulation Typeantagonist
PubMed IDs34003459; 32943948
CitationsFindling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH: Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status. CNS Drugs. 2021 Jun;35(6):643-653. doi: 10.1007/s40263-021-00825-w. Epub 2021 May 18.@@Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V: New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300. doi: 10.2147/JEP.S256586. eCollection 2020.
GroupsApproved; Investigational; Withdrawn
Direct ClassificationPhenol ethers
SMILESCCOC1=CC=CC=C1OCC1CNCCO1
Pathways
PharmGKB
ChEMBLCHEMBL306700